Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies

Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (mAbs) that block the PD-1/PD-L1 pathway continues to lead to the testing of multiple approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Ismael, Kocik-Krol, Justyna, Skalniak, Lukasz, Musielak, Bogdan, Wisniewska, Aneta, Ciesiołkiewicz, Agnieszka, Berlicki, Łukasz, Plewka, Jacek, Grudnik, Przemyslaw, Stec, Malgorzata, Siedlar, Maciej, Holak, Tad A., Magiera-Mularz, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483858/
https://www.ncbi.nlm.nih.gov/pubmed/37679783
http://dx.doi.org/10.1186/s12943-023-01853-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483858/
https://www.ncbi.nlm.nih.gov/pubmed/37679783
http://dx.doi.org/10.1186/s12943-023-01853-4

Ejemplares similares